InvestorsHub Logo
Followers 6
Posts 1400
Boards Moderated 0
Alias Born 08/24/2014

Re: chickpea598 post# 42450

Monday, 12/11/2017 11:01:30 PM

Monday, December 11, 2017 11:01:30 PM

Post# of 48316
Looking over the recent SEC filing Oncosec has about $22 million right now which includes the $9.3 million in warrant money raised.

Warrant Exercises

During the three months ended October 31, 2017, we received an immaterial amount of cash related to the exercise of outstanding warrants, and subsequent to October 31, 2017, we received gross proceeds of $9.3 million from the exercise of outstanding warrants (see “—November 2017 Warrant Exercise Inducement Offering” above). If the holders of all of our warrants that are outstanding as of the issuance of this report were to exercise all such warrants in full on a cash basis, we would receive an aggregate of approximately $27.4 million in net proceeds. However, the holders of these warrants may choose to exercise only a portion of the warrants they hold, may choose not to exercise any of the warrants they hold, or may choose to “net” exercise their warrants on a cashless basis to the extent permitted by the warrants. As a result, we may never receive meaningful, or any, proceeds from the exercise of these warrants.

If Oncosec reports good interim PISCES data mid-2018 this will probably trigger the outstanding warrants to be executed which will result in Oncosec banking another $27.4 million. Dilution should not be a problem because good results should lead to a licensing deal or buyout. If not, Oncosec will have around $40 million dollars to get commercialization started on their own....but that is absolutely not their intention. Dan O'Connor will make a deal....bank on it!